Cardiometabolic Health and Inflammatory Resolution
Recruiting
- Conditions
- Volunteers
- Registration Number
- NCT04256330
- Lead Sponsor
- Göteborg University
- Brief Summary
The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) or obese (\>30.0 kg/m2).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Informed signed consent has been obtained from the volunteer.
- The volunteer has a BMI greater than 18.5 kg/m2
Exclusion Criteria
- The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.
- An MD determines that the individual is on too many medications to participate
- The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.
- The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)
- The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.
- The individual has some form of chronic inflammation.
- The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).
- The individual uses immunosuppressive drugs (eg, methotrexate).
- The individual regularly consumes fish oils (omega 3).
- The individual has significant gastrointestinal problems.
- The individual smokes or uses chewing tobacco.
- The individual has been drinking alcohol two days before the study visit.
- The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination.
- The individual does not follow instructions given in the research study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammatory status 2027 The inflammatory status, defined as CRP levels and ability to respond to pro-resolving therapeutics, will be studied in all 6 groups
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways mediate inflammatory resolution in cardiometabolic health as studied in NCT04256330?
How do resolvins and lipoxins correlate with metabolic syndrome outcomes in lean, overweight, and obese populations?
Which inflammatory biomarkers predict cardiometabolic risk stratification in NCT04256330 observational study?
What adverse events are associated with chronic inflammation in obese individuals compared to lean controls in this trial?
How does NCT04256330's findings on inflammatory resolution compare to PPAR agonists in metabolic disease management?
Trial Locations
- Locations (1)
Gothenburg university
🇸🇪Gothenburg, Vastra Gotaland, Sweden
Gothenburg university🇸🇪Gothenburg, Vastra Gotaland, SwedenEmma Börgeson, PhDContact+46313420000emma.borgeson@wlab.gu.sePer-Anders Jansson, PhD, MDContact+46313420000Per-Anders.Jansson@wlab.gu.se
